Volume 18, Number 11—November 2012
Dispatch
Pandemic Influenza Virus Surveillance, Izu-Oshima Island, Japan
Table 1
Rapid diagnostic test results and prescription of anti-influenza agents in Izu-Oshima
Influenza season and influenza virus type* |
Prescriptions written at clinics, no. (%)
|
Total | ||||
---|---|---|---|---|---|---|
Oseltamivir† | Zanamivir‡ | Peramivir§ | Laninamivir¶# | None | ||
2008–09 | ||||||
A |
193 (53.5) § | 45 (12.5)§ | 0 | 0 | 124 (34.3) | 361 |
B |
39 (32.5) | 29 (24.2) | 0 | 0 | 52 (43.3) | 120 |
A + B |
2 (3.3) | 0 | 0 | 0 | 4 (66.7) | 6 |
Negative |
32 (5.5) | 10 (1.7) | 0 | 0 | 537 (92.8) | 579 |
2009–10 | ||||||
A |
219 (48.5) | 209 (46.2) | 0 | 0 | 24 (5.3) | 452 |
Negative |
42 (4.7) | 33 (3.7) | 0 | 0 | 828 (91.7) | 903 |
2010–11 | ||||||
A |
147 (66.2) | 52 (23.4) | 3 (1.4) | 0 | 20 (9.0) | 222 |
B |
60 (38.0) | 82 (51.9) | 1 (0.6) | 1 (0.6) | 14 (8.9) | 158 |
Negative |
44 (7.2) | 18 (3.0) | 0 | 0 | 548 (89.8) | 610 |
*Influenza virus type determined by rapid diagnostic test.
†Tamiflu, Chugai Pharmaceutical Co., Tokyo, Japan.
‡Relenza, GlaxoSmithKline, Research Triangle Park, NC, USA.
§Rapiacta, BioCryst Pharmaceuticals Inc., Durham, NC, USA; marketed since January 27, 2010.
¶Inavir, Daiichi Sankyo Co., Ltd., Tokyo, Japan; marketed since October 19, 2010.
#IIncludes 1 case for which Tamiflu and Relenza were prescribed.
1Current affiliation: Juntendo University Graduate School of Medicine, Tokyo.
2Current affiliation: Tokyo Institute of Technology, Yokohama, Japan.